Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-miniCHOP in patients over 80 with CD20+ diffuse large B-cell lymphoma
2007-001589-34Phase 2Completed
- Sponsor
- Groupe d'Étude des Lymphomes de l'Adulte
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Groupe d'Étude des Lymphomes de l'Adulte. Primary endpoint: Overall survival. Started Apr 2007; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-001589-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001589-34.